InVivoMAb Anti-Human Cannabinoid R1/CB1/CNR1 Antibody (5D12) (HB822010)

Name: InVivoMAb Anti-Human Cannabinoid R1/CB1/CNR1 Antibody (5D12)
Brand: abinScience
SKU: HB822010
Price: 370 USD
Availability: InStock

Fiche technique Partager le produit Copier les informations

Prix(USD) :

Spécification :

100ug
1mg

Nombre :

Contactez-nous

Aperçu
Images
Reférences
Fiche technique
SDS

Aperçu

Numéro de catalogue

HB822010

Description

InVivoMAb Anti-Human CNR1/CB1 Nanobody (5D12) [5D12] (HB822010) is a alpaca monoclonal antibody detecting CNR1 in ELISA, Neutralization. Suitable for Human.

Reactivité des espèces

Human

Applications

ELISA, Neutralization, WB

Espèce hôte

Alpaca

Clonalité

Monoclonal

Isotype

VHH-8His-Cys-tag

ID de clone

5D12

Applications testées

Cible

CNR1, CB1, CANN6, CB-R, CNR, Cannabinoid receptor 1

Niveau d'endotoxines

<0.01 EU/ug

Pureté

>95% as determined by SDS-PAGE.

Produits associés

pH 7.4 Dilution Buffer

Purification

Purified by Nickel column.

Numéro d'accès

P21554

Forme

Liquid

Tampon de stockage

0.01M PBS pH 7.4

Reférez-vous aux informations spécifiques sur le tampon dans la copie papier du datasheet ou dans le COA spécifique au lot.

Informations d'utilisation du produit

Application	Dilution
WB	1:500-1:2000

Stabilité et stockage

Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.

Contexte

Cannabinoid receptor 1 (CNR1/CB1) is a ~52 kDa protein. G-protein coupled receptor for endogenous cannabinoids (eCBs), including N-arachidonoylethanolamide (also called anandamide or AEA) and 2-arachidonoylglycerol (2-AG), as well as phytocannabinoids, such as delta(9)-tetrahydrocannabinol (THC). Mediates many cannabinoid-induced effects, acting, among others, on food intake, memory loss, gastrointestinal motility, catalepsy, ambulatory activity, anxiety, chronic pain. Signaling typically involves reduction in cyclic AMP. In the hypothalamus, may have a dual effect on mitochondrial respiration depending upon the agonist dose and possibly upon the cell type. Increases respiration at low doses, while decreases respiration at high doses.

1. Ryberg, E. et al. (2005) FEBS letters 579, 259-64. PMID: 15620723

2. Hua, T. et al. (2016) Cell 167, 750-762.e14. PMID: 27768894

3. Shao, Z. et al. (2016) Nature 540, 602-606. PMID: 27851727

4. Yang, X. et al. (2022) Nature chemical biology 18, 831-840. PMID: 35637350

5. Gérard, CM. et al. (1991) The Biochemical journal 279 ( Pt 1), 129-34. PMID: 1718258

6. Oddi, S. et al. (2012) British journal of pharmacology 165, 2635-51. PMID: 21895628

7. Niehaus, JL. et al. (2007) Molecular pharmacology 72, 1557-66. PMID: 17895407

8. Jourdan, T. et al. (2013) Nature medicine 19, 1132-40. PMID: 23955712

Note

For research use only. Not suitable for clinical or therapeutic use.

Images

SDS-PAGE

SDS-PAGE for InVivoMAb Anti-Human CNR1/CB1 Nanobody (5D12)
Bioactivity

Detects recombinant CNR1 (Catalog No: HB822012) in indirect ELISA.
Western blot

Western blot analysis was performed using anti-CNR1 monoclonal antibody at 1ug/mL on various samples.
Lane 1: recombinant human CNR1 (Catalog No: HB822012)
Immunofluorescence

Immunofluorescence staining of SHSY5Y with Alpaca monoclonal antibody (20ug/ml, overnight at 4°C), followed by Alexa Fluor-488-conjugated secondary antibody (6.5ug/ml, 50minutes at room temperature). The target protein was detected in the Cell membrane，Cytoplasm.